AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

Shots:AbbVie and IGI Therapeutics, a subsidiary of Ichnos Glenmark Innovation, have entered into an exclusive licensing deal for ISB 2001, a drug targeting oncology & autoimmune diseases developed using IGI's proprietary BEAT protein platformAs per the deal, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe,…

ByDipanshu Dixit2 days ago

News

HanchorBio Out-Licenses HCB101 to Shanghai Henlius Biotech For ~$202M

SShots:HanchorBio entered into an out-licensing agreement with Shanghai Henlius Biotech and granted exclusive rights to develop and commercialize HCB101 in Greater China, Southeast Asia, and MENAUnder the terms and agreement, HanchorBio will receive $10M upfront and up to $192M in development and regulatory milestones, plus tiered royaltiesHenlius will also oversee development,…

ByPrince GiriJuly 1, 2025

News

Ollin Biosciences Signs a ~$440M Licensing Agreement with VelaVigo Bio for VBS-102

Shots:VelaVigo Bio has granted Ollin Biosciences an exclusive license to develop, manufacture & commercialize VBS-102 worldwide, except Greater China, where VelaVigo will maintain its rightsAs per the deal, VelaVigo will receive an upfront payment along with development, regulatory, & commercial milestones in cash & equity, making an aggregate of ~$440M, plus tiered royalties…

ByRidhi RastogiApril 21, 2025

AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

HanchorBio Out-Licenses HCB101 to Shanghai Henlius Biotech For ~$202M

Ollin Biosciences Signs a ~$440M Licensing Agreement with VelaVigo Bio for VBS-102

Contact US

OUR INFORMATION

FOLLOW US